Today: 13 May 2026
AEVEX Stock Jumps 35% After $320 Million Drone IPO as AVEX Tests Defense-Tech Demand
18 April 2026
2 mins read

AEVEX Stock Jumps 35% After $320 Million Drone IPO as AVEX Tests Defense-Tech Demand

NEW YORK, April 18, 2026, 14:32 EDT

  • AEVEX wrapped up its debut on the NYSE at $26.93, topping its IPO price of $20.
  • Solana Beach’s defense-tech company sold 16 million shares, pulling in $320 million.
  • Investors are circling drone makers linked to U.S. and allied defense contracts as the listing hits the market.

AEVEX Corp. jumped out of the gate, finishing its debut on the New York Stock Exchange roughly 35% above its $20 IPO price. The military-drone maker, which pulled in $320 million from the offering, wrapped up Friday at $26.93, opening the door for public investors to tap into the autonomous defense sector.

No coincidence on the timing. Drones and loitering munitions—the kind that linger near their mark before attacking—plus a host of unmanned systems have become central to military strategy, thanks to their widespread deployment in Ukraine and the Middle East. Governments have responded by ramping up investment in speedier, lower-cost tech for the battlefield.

AEVEX is drawing attention these days as it operates in a crowded spot within the defense sector—not quite a top-tier prime, but far from a niche tech upstart. Its business centers on unmanned aircraft systems (UAS), plus sensor integration, aircraft upgrades, and ISR—industry shorthand for intelligence, surveillance and reconnaissance, or military info gathering and analysis.

Solana Beach, California’s AEVEX priced 16 million Class A shares at $20 apiece, landing inside the $18 to $21 range pitched to investors. Underwriters picked up a 30-day window for up to 2.4 million additional shares. The deal should wrap up on April 20, pending routine closing conditions.

Goldman Sachs, BofA Securities, and Jefferies took the lead on the deal. J.P. Morgan, RBC Capital Markets, and Baird were named as additional bookrunners, while William Blair, Raymond James, and Needham & Co. also appeared on the underwriter lineup.

AEVEX’s recent filing spelled out why investors shrugged off its short track record on the public markets. For the first quarter, the company put revenue in the $200 million to $208 million range—leaping from $53.3 million a year ago—largely thanks to growth in its Tactical Systems segment and momentum from the EUCOM AOR Deep Strike program. It also projected net income of $19 million to $22.5 million, swinging from a $27.3 million loss in the prior year.

AEVEX turned in $432.9 million in revenue for 2025, but closed the year with a net loss of $16.8 million. The company’s funded backlog was roughly $503 million at the end of the period. According to Washington Technology, about 78% of AEVEX’s sales came from U.S. government contracts.

Chief Executive Roger Wells linked the decision to list directly to Pentagon appetite. “Over $50 billion was requested for unmanned autonomous systems, and that’s absolutely in the sweet spot of the systems and capabilities we provide,” Wells told Reuters. Reuters

The Tactical Systems segment at AEVEX pulled in 74.4% of 2025 revenue, its filing shows. That group works on designing and making autonomous defense systems. Over in Global Solutions, the focus is aircraft modification, engineering support, and mission services—covering both manned and unmanned platforms.

The list of public comps remains short, though it’s expanding. AEVEX now sits on the market with other unmanned-systems players like Kratos Defense & Security Solutions and AeroVironment. On the private side, defense-tech outfits such as Anduril Industries and Shield AI are also chasing military contracts.

Still, the risk that makes AEVEX attractive is baked into the story. The company leans hard on government spending—at year-end, 84% of its funded backlog was with the U.S. government, according to its filing. That reliance isn’t without peril; U.S. government programs aren’t set in stone and can face delays, funding cuts, or be scrapped with little warning. All it takes is a budget standoff, a contract dispute, or a canceled program to throw off its revenue trajectory.

AEVEX landed an impressive opening trade, but ringing the bell is only the beginning. The real challenge: turning surging wartime demand into steady, reportable numbers quarter after quarter.

Stock Market Today

  • 10x Genomics Shares Drop 5.3% After Q1 Revenue Miss Raises Growth Fears
    May 13, 2026, 12:21 AM EDT. 10x Genomics (TXG) shares fell 5.3% following quarterly results that beat forecasts but showed a 2.6% revenue decline year-over-year to $150.8 million. Despite narrowing losses and reconfirming full-year guidance, investors reacted to concerns about future growth prospects. The stock closed at $21.61, down 3.6% from the previous close. Volatility remains high with 54 price swings over 5% in the past year. Investor caution appears linked to weaker growth signals in the life sciences sector, highlighted by peer Thermo Fisher's slower organic revenue gain. Although 10x Genomics is up 29.9% year-to-date, shares remain 17.2% below their 52-week peak. The market seems to weigh near-term sales softness against long-term potential cautiously.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 13.05.2026

13 May 2026
LIVEMarkets rolling coverageStarted: May 13, 2026, 12:00 AM EDTUpdated: May 13, 2026, 12:21 AM EDT 10x Genomics Shares Drop 5.3% After Q1 Revenue Miss Raises Growth Fears May 13, 2026, 12:21 AM EDT. 10x Genomics (TXG) shares fell 5.3% following quarterly results that beat forecasts but showed a 2.6% revenue decline year-over-year to $150.8 million. Despite narrowing losses and reconfirming full-year guidance, investors reacted to concerns about future growth prospects. The stock closed at $21.61, down 3.6% from the previous close. Volatility remains high with 54 price swings over 5% in the past year. Investor caution appears linked to weaker
US Stocks Lose Their Record Edge After Hours as Oil Turns Inflation Into a Fed Problem

US Stocks Lose Their Record Edge After Hours as Oil Turns Inflation Into a Fed Problem

13 May 2026
Tech stocks led declines Tuesday after April CPI data showed consumer prices rose 0.6% for the month and 3.8% year-over-year, pushing Treasury yields higher and weighing on rate-cut hopes. Brent crude settled above $107, fueling inflation concerns. The S&P 500 slipped 11.88 points to 7,400.96, while the Nasdaq lost 185.92 to 26,088.20. Chip stocks fell sharply, with Qualcomm down 11% and Intel off 6.8%.
Karman Stock’s Rally Turns Into an Earnings Test as Backlog Jumps and Valuation Bites

Karman Stock’s Rally Turns Into an Earnings Test as Backlog Jumps and Valuation Bites

13 May 2026
Karman Holdings shares closed up 6.2% at $62.48 on May 12, then fell 11% after hours following first-quarter results and a raised 2026 outlook. Q1 revenue jumped 51% to $151.2 million, net income reached $7.8 million, and backlog hit $1.0 billion. Adjusted EPS matched the $0.11 estimate. The company announced over $1 billion in new contingent demand commitments.
NuScale Power Stock Jumps as Fluor’s $150 Million SMR Share Sale Lands
Previous Story

NuScale Power Stock Jumps as Fluor’s $150 Million SMR Share Sale Lands

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026
Next Story

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Go toTop